Trials / Completed
CompletedNCT02952534
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 277 (actual)
- Sponsor
- pharmaand GmbH · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rucaparib | Rucaparib will be administered daily |
Timeline
- Start date
- 2017-02-15
- Primary completion
- 2021-07-18
- Completion
- 2021-07-27
- First posted
- 2016-11-02
- Last updated
- 2023-06-09
- Results posted
- 2022-06-08
Locations
149 sites across 12 countries: United States, Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Israel, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02952534. Inclusion in this directory is not an endorsement.